Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster Study of GSK's 10-valent Pneumococcal Conjugate Vaccine vs 23-valent Polysaccharide Vaccine in Children
NCT00307567Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2005
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised trial of 10-valent pneumococcal conjugate vaccine in pneumococcal infection (2 arms), sponsored by GSK. Primary endpoint: Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C antibody concentrations. Started Nov 2005; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00307567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307567.